Leadership Transition at Altimmune
In a significant shift at the helm, Altimmune, Inc. (NASDAQ: ALT) has announced a CEO transition that will see Jerry Durso step in as President and Chief Executive Officer, succeeding Dr. Vipin Garg, effective January 1, 2026. This strategic move follows Dr. Garg's impactful seven-year leadership stint, which has been instrumental in navigating the company’s trajectory toward becoming a prominent clinical-stage biopharmaceutical entity.
Reflecting on Past Achievements
Dr. Garg has played a pivotal role in transforming Altimmune into a dynamic clinical-stage company. Under his leadership, the company advanced its leading candidate, pemvidutide, from a nascent preclinical molecule to a Phase 3-ready program targeting metabolic dysfunction-associated steatohepatitis (MASH). The ongoing clinical trials in alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) also reflect the breadth of Altimmune's innovative approach.
Insights from Dr. Garg and Mr. Durso
"Serving as CEO of Altimmune has been an immense privilege, and I am proud of our team's accomplishments,” Dr. Garg shared. He emphasized the foundation laid with pemvidutide and expressed confidence in Durso's ability to guide the company forward. Jerry Durso, newly appointed as CEO, expressed enthusiasm about leading Altimmune through its next growth phase, believing in pemvidutide’s potential to transform the treatment landscape for patients with liver diseases.
Details on the Drug Candidate
Pemvidutide, a dual glucagon and GLP-1 receptor agonist, has shown promising results, including notable reductions in liver inflammation and fibrosis, alongside significant weight loss in MASH patients. The upcoming End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) is crucial for aligning on trial designs and endpoints for the anticipated Phase 3 MASH program.
Future Path for Altimmune
This transition in leadership is not just a change in roles but also signals the company’s commitment to advancing its core mission. Jerry Durso brings over 30 years of leadership experience within the life sciences sector. His prior tenure at Intercept Pharmaceuticals focused on liver diseases aligns perfectly with Altimmune’s goals. His proven track record includes guiding companies through complex corporate strategies and building successful product franchises.
Durso’s Vision for the Company
Durso is looking forward to harnessing the potential of pemvidutide to deliver significant benefits to patients. His remarks underscore a clear vision for enhancing stakeholder value and positioning Altimmune as a forefront player in the biopharmaceutical market. His admiration for Dr. Garg and the groundwork he laid reflects a smooth transition that seeks to maintain continuity in the company’s strategic efforts.
About Altimmune
Altimmune specializes in creating innovative peptide-based therapeutics aimed at liver and metabolic diseases. The company aims to improve patient care significantly through its lead product candidate, pemvidutide, specifically targeting conditions like MASH, AUD, and ALD.
Frequently Asked Questions
What prompted the CEO transition at Altimmune?
The transition is part of a planned leadership change where Jerry Durso will succeed Dr. Vipin Garg to enhance the company's strategic direction in its clinical-stage development.
What has been Dr. Garg's impact on Altimmune?
Dr. Garg has successfully guided Altimmune through significant advancements, particularly with the pemvidutide program, propelling it from preclinical to Phase 3 readiness.
What is pemvidutide?
Pemvidutide is a dual glucagon and GLP-1 receptor agonist designed for treating liver-related conditions, having demonstrated positive results in reducing liver inflammation and fibrosis.
What are Altimmune’s future clinical plans?
Altimmune plans to report 48-week data from the IMPACT Phase 2b trial soon, alongside preparing for an End-of-Phase 2 meeting with the FDA regarding its Phase 3 program.
How does Durso's experience benefit Altimmune?
With over 30 years of experience in the life sciences and a background in liver diseases, Durso brings invaluable expertise to lead Altimmune's growth and commercialization efforts effectively.
